The association between NT-proBNP levels, functional capacity and stage in patients with heart failure

Acta Cardiologica

Volumn 60, Issue 6, 2005, Pages 631-638

  Karabulut, Aziz ^a   Kaplan, Abdurrahman ^a   Aslan, Cetin ^a   Iltumur, Kenan ^a   Toprak, Gulten ^a   Toprak, Nizamettin ^a  

^a DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Heart failure; NT proBNP; NYHA classification; Stage

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BRAIN NATRIURETIC PEPTIDE; CHLORIDE; CHOLESTEROL; CREATININE; GLOBULIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROHORMONE; POTASSIUM; SODIUM; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; FEMALE; FUNCTIONAL ASSESSMENT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE FUNCTION; HUMAN; IMMUNOASSAY; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PREDICTION; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; TRANSTHORACIC ECHOCARDIOGRAPHY;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROBABILITY; RADIOIMMUNOASSAY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 28944451194     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.60.6.2004936     Document Type: Article

References (38)

1. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-60.
2. Mair J, Friedl W, Thomas S, Puschendorf B. Natriuretic peptides in assesment of left-ventricular dysfunction. Scand J Clin Lab Invest 1999; 59: 132-42.
3. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, Smith SC; American College of Cardiology; American heart Association. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. J Heart Lung Transplant 2002; 21: 189-203.
4. van den Broek SA, van Veldhuisen DJ, de Graeff PA, Landsman ML, Hillege H, Lie KI. Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 70: 359-63.
5. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
6. McMurray J, McDonagh T, Morrison CE, Dargie HJ. Trends in hospitalization for heart failure in Scotland 1980-1990. Eur Heart J 1993; 14: 1158-62.
7. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, Tunstall-Pedoe H, McMurray JJ, Dargie HJ. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
8. Lerman A, Gibbons RJ, Rodeheffer RJ, Bailey KR, McKinley LJ, Heublein DM, Burnett JC Jr. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993; 341: 1105-9.
9. Matsumoto N, Akaike M, Nishiuchi T, Kawai H, Saito S. Different secretion profiles of atrial and brain natriuretic peptides after acute volume loading in patients with ischemic heart disease. Acta Cardiol 1997; 52: 261-72.
10. Yamamoto K, Burnett JC Jr, Jougasaki M, Nishimura RA, Bailey KR, Saito Y, Nakao K, Redfield MM. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28: 988-94.
11. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Mabuchi N, Hayashi M, Ohnishi M, Sawaki M, Fujii M, Horie H, Sugimoto Y, Kinoshita M. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999; 20: 1799-807.
12. Hall C, Rouleau JL, Moye L, de Champlain J, Bichet D, Klein M, Sussex B, Packer M, Rouleau J, Arnold MO. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation 1994; 89: 1934-42.
13. Levin ER, Gardner DG, Samson WK. Natriuretic peptides (review). New Engl J Med 1998; 339: 321-8.
14. de Bold A. Heart atria granularity: effects of changes in water-electrolyte balance. Proc Soc Exp Biol Med 1979; 161: 508-11.
15. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28: 89-94.
16. Sudoh T, Kangawa K, Minamino N, Matsuo H. A natriuretic peptide in porcine brain. Nature 1998; 322: 78-81.
17. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-typenatriuretic peptide: a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990; 168: 863-70.
18. Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system I: natriuretic peptides. J Hypertens 1992; 10: 907-12.
19. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 1990; 82: 1724-9.
20. Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL, Pandey KN, Milgram SL, Smithies O, Maeda N. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci U.S.A. 1997; 94: 14730-5.
21. Margulies KB, Heublein DM, Perrella MA, Burnett JC Jr. ANF-mediated renal cGMP generation in congestive heart failure. Am J Physiol 1991; 260: F562-F568.
22. Redfield MM, Edwards BS, Heublein DM, Burnett JC Jr. Restoration of renal response to atrial natriuretic factor in experimental low-out heart failure. Am J Physiol 1989; 257: R917-R923.
23. Abassi ZA, Haramati A, Hoffman A, Burnett Jr J.C, Winaver J. Effect of converting-enzyme inhibition on renal response to ANF in rats with experimental heart failure. Am J Physiol 1990; 259: R84-R89.
24. Valli N, Gobinet A, Bordenave L. Review of 10 years of the clinical use of brain natriuretic peptide in cardiology. J Lab Clin Med 1999; 134(5): 437-44.
25. Muders F, Kromer EP, Griese DP, Pfeifer M, Hense HW, Riegger GA, Elsner D. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am Heart J 1997; 134: 442-9.
26. Yu CM, Sanderson JE, Shum IO, Chan S, Yeung LY, Hung YT, Cockram CS, Woo KS. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with restrictive filling pattern. Eur Heart J 1996; 17: 1694-702.
27. Tsuji H, Nishino N, Kimura Y, Yamada K, Nukui M, Yamamoto S, Iwasaka T, Takahashi H. Haemoglobin level influences plasma brain natriuretic peptide concentration. Acta Cardiol 2004; 59(5): 527-31.
28. Murdoch DR, Byrne J, Morton JJ, McDonagh TA, Robb SD, Clements S, Ford I, McMuray JJ, Dargie HJ. Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implications for clinical practice. Heart 1997; 78: 594-7.
29. Davidson NC, Coutie WJ, Struthers AD. N-terminal proatrial natriuretic peptide and brain natriuretic peptide are stable for up to 6 hours in whole blood in vitro. Circulation 1995; 91: 1276-81.
30. Bevilacqua M, Vago T, Baldi G, Norbiato G. Analytical agreement and clinical correlates of plasma natriuretic peptide measured by three immunoassays in patients with heart failure. Clin Chem 1997; 43: 2439-40.
31. Cleland JG, Gemmell I, Khand A, Boddy A. Is the prognosis of heart failure improving? Eur J Heart Fail 1999; 1: 229-41.
32. The SOLVD investigators. Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 321: 685-91.
33. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Ikram H, Crozier IG, Smyth DW. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97(19): 1921-9.
34. Gray SF, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Toretsky ER, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 1990; 82: 724-9.
35. Nozaki N, Yamaguchi S, Shirakabe M, Nakamura H, Tomoike H. Soluble tumor necrosis factor receptors are elevated in relation to severity of congestive heart failure. Jpn Circ J 1997; 61(8): 657-64.
36. Gottlieb SS, Kukin ML, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989; 13: 1534-9.
37. Kurum T, Yuksel M, Ozbay G, Soyuk S, Ture M. Relationship with plasma neurohormones and dyssynchrony detected by Doppler echocardiography in patients undergoing permanent pacemaker implantation. Acta Cardiol 2003; 58(6): 499-505.
38. Jensen KT, Carstens J, Ivarsen P, Pedersen EB. A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases. Scand J Clin Lab Invest 1997; 57, 529-40.